COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:

Key Record Dates Identifier: NCT03234153
Brief Title: Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin (NITIMIB)

First Submitted : July 26, 2017
First Submitted that Met QC Criteria : July 26, 2017
First Posted : July 31, 2017

Last Update Submitted that Met QC Criteria : June 16, 2020
Last Update Posted : June 17, 2020